Related Experiment Video

Updated: Apr 18, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer

Carole Helissey1, Stephane Champiat, Jean-Charles Soria

  • 1Department of Drug Development and South Paris University, Gustave Roussy Cancer Campus, Villejuif, France.

Current Opinion in Oncology
|January 21, 2015
PubMed
Abstract

Insights

Immune checkpoint inhibitors (ICIs) show promise in treating metastatic nonsmall cell lung cancer (NSCLC) by boosting antitumor immunity. Further trials are expected to confirm their efficacy and durability in NSCLC treatment.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic nonsmall cell lung cancer (NSCLC) remains a significant health challenge.
  • Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy.
  • Restoring antitumor immunity is a key mechanism of action for ICIs.

Purpose of the Study:

  • To review the efficacy and toxicity of current immune checkpoint inhibitors (ICIs) in NSCLC.
  • To explore novel checkpoints and combination therapies for NSCLC.
  • To discuss the role of programmed cell death-L1 (PD-L1) as a biomarker.

Main Methods:

  • Literature review of clinical trials and research studies.
  • Analysis of efficacy and toxicity data for ICIs in NSCLC.
  • Evaluation of ongoing and planned phase II and III trials.

Main Results:

  • ICIs demonstrate promising activity and durable responses in NSCLC patients.
  • Specific patterns of tumor response and immune-related toxicities are associated with immunotherapy.
  • Combination studies of ICIs are under investigation to enhance therapeutic outcomes.

Conclusions:

  • Future challenges in the clinical application of ICIs in NSCLC need to be addressed.
  • Further research is required to optimize ICI therapy and identify predictive biomarkers.
  • The development of ICIs represents a significant advancement in NSCLC treatment.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K